



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020539/S-018

SUPPLEMENT APPROVAL

Novartis Pharmaceuticals Corporation
Attention: Raffy Chilingirian, DMH, MS, BBA, CCRA
RBRM, Drug Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936-1080

Dear Mr. Chilingirian:

Please refer to your Supplemental New Drug Application (sNDA) dated August 2, 2010, received August 3, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lamisil (terbinafine hydrochloride) Tablets, 250 mg.

We acknowledge receipt of your amendments dated September 3, 2010, December 21, 2010, and February 25, 2011.

This "Prior Approval" supplemental new drug application provides for changes to the Warnings and Precautions section of the labeling.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revisions listed below.

- In Highlights of Prescribing Information under WARNINGS AND PRECAUTIONS, the words "may be" were added before "prolonged" and before "permanent" in bullet number 2.
- In Highlights of Prescribing Information under WARNINGS AND PRECAUTIONS, the words "may be" were added before "permanent" in bullet number 3.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to, except with the revisions listed, the enclosed labeling (text for the package insert, text for the patient package insert) with the addition of any labeling changes

in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions listed approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Matthew White, Regulatory Project Manager, at (301) 796-4997.

Sincerely,

{See appended electronic signature page}

Tatiana Oussova, M.D., M.P.H.
Deputy Director for Safety
Division of Dermatology and Dental Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

GORDANA DIGLISIC
03/29/2011